# Effect of Fenofibrate on Markers of Gut Barrier Function in Dogs With Naturally Occurring Diabetes Mellitus

## TL;DR

This study examines how fenofibrate affects gut barrier function and lipid levels in dogs with naturally occurring diabetes.

## Contribution

The study is the first to evaluate fenofibrate's effects on gut barrier markers in dogs with naturally occurring diabetes.

## Key findings

- Fenofibrate reduced serum lipopolysaccharide concentrations by 15% after 21 days.
- Serum triglycerides and cholesterol decreased significantly with fenofibrate treatment.
- No changes were observed in markers of systemic or pancreatic inflammation.

## Abstract

Fenofibrate improves gut barrier function and reduces serum lipids in purpose‐bred dogs with induced diabetes mellitus (DM), but its effects in dogs with naturally occurring DM are unknown.

Determine the effects of fenofibrate on markers of systemic and pancreatic inflammation, markers of gut barrier function, lipoprotein profiles, and glycemic control in dogs with naturally occurring DM.

Sixteen client‐owned dogs with naturally occurring, uncomplicated DM.

Longitudinal cohort study. Dogs were treated with fenofibrate (Tricor, 6–10 mg/kg, P.O., once daily) for 21 days. Interstitial glucose, serum cytokines, lipopolysaccharide (LPS), pancreatic lipase, and lipid profiles were compared between baseline and day 21 using paired t‐tests and Wilcoxon signed‐rank tests.

Fenofibrate had no effect on glycemic control, serum cytokines, or serum pancreatic lipase. Compared to baseline, the concentrations of serum LPS decreased at day 21 by (mean ± SD) 15 ± 24% (95% CI 2–28%, p = 0.03), serum triglycerides decreased by 36 ± 39% (95% CI 15–56%, p = 0.002), and serum cholesterol decreased by 20 ± 14% (95% CI 12–28%, p < 0.0001).

Fenofibrate treatment was not associated with a decrease in markers of systemic or pancreatic inflammation. In diabetic dogs, short‐term fenofibrate treatment appears to be safe, and the improvement in gut barrier function and lipid profiles might lead to long‐term benefits, such as reduction in pancreatitis risk and frequency of signs of gastrointestinal disease.